Prof Olivier Glehen is an expert in Surgery at Centre Hospitalier Lyon Sud (France). As of October 2026, ScienceLeadR ranks Olivier Glehen in the top 1% of experts worldwide for Abdominal Neoplasms, Peritoneal Neoplasms and Adenoma. Olivier Glehen has authored 664 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 1 of them ongoing. SLR score: 2,219 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Olivier Glehen Centre Hospitalier Lyon Sud France
2 219 ScienceLeadR Reputation 2219
Network Map

Surgery

Subspecialties: Oncology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2000 - 2026

Source: PubMed

Centre Hospitalier Lyon Sud

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 664

Citations

Citations: 27 918 1st author: 44 Last author: 149 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Sarcopenia and outcomes after CRS ± HIPEC for gastric peritoneal metastases: no association with major morbidity and poorer survival in synchronous disease.
PMID 42664832 — muscles, hyperthermic intraperitoneal chemotherapy, body composition, neoplasm metastasis, morbidity, medical oncology, sarcopenia
Eur J Surg Oncol20260
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for pancreatic cancer peritoneal metastases: A retrospective multicentric study from the ISSPP PIPAC Database.
PMID 42648232 — registries, pancreatic neoplasms, paclitaxel, pharmaceutical preparations, aerosols, neoplasms, disease progression, drug therapy, neoplasm metastasis, diagnosis, peritoneal neoplasms, therapeutics, medical oncology, prognosis, chemotherapy, pressurized intraperitoneal aerosol chemotherapy
Eur J Surg Oncol20260
Comparison of surgical and oncological outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in upper and middle/lower rectal peritoneal metastases.
PMID 42648158 — cytoreduction surgical procedures, hyperthermia, induced, hyperthermic intraperitoneal chemotherapy, drug therapy, neoplasm metastasis, risk factors, chemotherapy
Surg Oncol20260
Evaluating quality of colorectal cancer surgery across elective and emergency health systems: secondary analysis of prospective cohort studies in 95 countries.
PMID 42483900 — global health, emergencies, surgical procedures, operative, neoplasms, income, cohort studies, colorectal neoplasms
BJS Open20260
Impact of postoperative chemotherapy in patients resected for esophagogastric adenocarcinoma with major pathological response after preoperative chemotherapy: a study from the FREGAT database.
PMID 42466102 — neoplasms, adenocarcinoma, drug therapy, chemotherapy
Ther Adv Med Oncol20260

Clinical Studies 25

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6

By phase:

N/A 14
Phase 3 7
Phase 1/Phase 2 2
Phase 2 2

By status:

Completed 11
Unknown 7
Recruiting 4
Terminated 2
Active not recruiting 1

By type:

Interventional 14
Observational 11

By Monocentric/Multicentric:

monocentric 11
multicentric2to4 3
multicentric5to9 1
multicentricup10 10

Main Topics

Cohort/Consortium Investigators 21

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
CIRculating CANcer MAster Protocol
NCT05089747 — cells, blood, blood specimen collection, micrornas, neoplasms, biopsy, cell-free nucleic acids, biomarkers, nucleic acids, diagnosis, therapeutics, circulating microrna, dna, liquid biopsy
N/ARecruiting2022

LeadR Networks

Main global connection map